← Back to scans

When will WHOOP, Inc. officially announce an IPO?

KXIPOWHOOP-27JAN01 · Economics · 2026-04-03
10%
Multi-Step
10%
Market Price
+0.0%
Edge
50%
Confidence
Final Rationale
I ACCEPT most of the Devil's Advocate critiques. Challenge 3 (math inconsistency) is valid — a proper conditional chain of the sub-questions yields a much lower probability than my weighted average approach. Challenge 5 is correct that the March 2026 $575M Series G is the dominant signal: there is virtually no institutional logic for a company to announce an IPO within 9 months of closing a mega-round at $10.1B valuation. Challenge 2 rightly notes that 'last private round' is a common CEO talking point that doesn't reliably predict near-term IPOs. Challenge 7 correctly identifies that my 15% estimate exceeded even my own 18-month base rate despite the compressed 9-month window. The market at 10% with a strongly one-sided orderbook is consistent with the structural reality, and I lack specific evidence (such as named underwriters, S-1 filing, or concrete timeline commitments) to justify deviating upward from it. The residual 10% probability reflects the non-zero chance that WHOOP's strategic investors (Abbott, Mayo Clinic) push for a rapid public listing or that market conditions create an irresistible IPO window.
What Would Change My Mind
An S-1 filing or credible report of WHOOP hiring underwriters (Goldman, Morgan Stanley, etc.) would push this above 50%. A CEO statement with a specific timeline (e.g., 'we plan to IPO in Q4 2026') would push to 40%+. Conversely, another private funding round or executive departures would push below 5%.
1. Planning Agent Sonnet
binary economics kalshi_data kalshi_orderbook article_search web_search
Sub-questions
IDQuestionWeight
sq1 Has WHOOP, Inc. already filed an S-1 or publicly announced IPO plans as of mid-2025? 25%
sq2 Will WHOOP, Inc. achieve sufficient financial metrics (revenue growth, profitability path) to support an IPO by end of 2026? 30%
sq3 Will IPO market conditions (investor appetite for consumer tech/wearables, overall market sentiment) be favorable enough for WHOOP to go public before Jan 1, 2027? 25%
sq4 Has WHOOP, Inc. raised recent funding rounds or hired underwriters/bankers signaling imminent IPO preparation? 20%
Reasoning Approach
WHOOP is a consumer wearable health tech company that has remained private for years with multiple funding rounds at high valuations. The key analytical challenge is distinguishing between a company that is IPO-ready vs. one that is still building toward exit. Reference classes: consumer health/wearables companies (Fitbit, Oura still private) suggest the space is not always IPO-friendly; broader tech IPO cycles matter (2021 boom, 2022-2023 drought, gradual 2024-2025 recovery). Causal mechanisms: WHOOP would need favorable market conditions, strong subscription revenue metrics, and a strategic decision to tap public markets rather than raise another private round. Key differentiators: WHOOP competes with Apple Watch and Garmin while maintaining a subscription model, which is attractive to public markets but requires scale. Check for recent banker hires, S-1 filings, or management statements about public markets. The 18-month window (to Jan 2027) is meaningful — not immediate, but not indefinitely long. Base rate for any specific private unicorn IPO-ing within an 18-month window is low (~10-20%) unless there are clear signals.
2. Research Execution No LLM
ToolStatusTime
kalshi_data OK 3.07s
kalshi_orderbook OK 0.1s
article_search OK 0.82s
web_search OK 42.79s
3. Evidence Synthesis Sonnet · 17 items
#StrengthDirectionSourceClaimPriced In
1 MODERATE ↓ DOWN web_search As of early April 2026, WHOOP has not filed an S-1 with the SEC. No official IPO announcement has been made, though CEO Will Ahmed stated in November 2025 that an IPO is the next step and that the Series G is expected to be the last private round. No
2 STRONG ↑ UP web_search WHOOP raised a $575 million Series G round at a $10.1 billion valuation on March 31, 2026, led by Collaborative Fund with participation from QIA, Mubadala, Abbott, and Mayo Clinic. CEO explicitly framed this as the last private round before an IPO. No
3 MODERATE ↑ UP web_search CEO Will Ahmed told Bloomberg in November 2025 he was considering going public, but no specific IPO timeline was disclosed and no underwriters have been named. Yes
4 WEAK ↓ DOWN web_search WHOOP is described as 'eyeing an IPO as soon as in the next two years' with no fixed timeline disclosed as of the research date. No
5 MODERATE ↑ UP web_search WHOOP's valuation nearly tripled from $3.6 billion (2021 Series F) to $10.1 billion (2026 Series G), suggesting strong investor confidence in its growth trajectory, though no revenue or profitability figures were disclosed. No
6 MODERATE ↑ UP article_search WHOOP launched new hardware (Whoop 5.0 and Whoop MG) in May 2025 with significantly improved battery life and processing speed, marking its first major hardware update since 2021 — signaling product investment ahead of a potential public offering. Yes
7 STRONG ↓ DOWN article_search FDA issued a warning letter to WHOOP in July 2025 over its Blood Pressure Insights feature, alleging unauthorized medical device marketing. WHOOP contested the FDA's authority, creating regulatory risk that could complicate IPO readiness. Yes
8 MODERATE ↑ UP web_search WHOOP's $575M Series G includes strategic investors Abbott and Mayo Clinic, suggesting health-focused revenue partnerships are being developed — potentially strengthening the subscription revenue story for public markets. No
9 STRONG ↑ UP article_search The IPO market showed strong recovery in mid-2025, with high-profile successful IPOs from Circle (500% surge), Klarna ($17B IPO, 30% pop), Chime, eToro, and Hinge Health — indicating improving conditions for large tech/consumer IPOs. Yes
10 MODERATE — NEUTRAL article_search IPO market analysts as of mid-2025 expected a 'return to normalcy' rather than a 2020-2021 style boom, suggesting conditions are favorable but not euphoric for large unicorn listings. Yes
11 WEAK ↑ UP article_search Fitness wearable demand is growing, with RFK Jr. promoting wearables for all Americans and sales of fitness tracking devices up — potentially improving the consumer appetite narrative for WHOOP's IPO story. Yes
12 MODERATE ↑ UP article_search The S&P 500 reached record highs in late October 2025 and broader market earnings seasons were strong in early 2026, suggesting supportive macro backdrop for IPOs through early 2026. Yes
13 MODERATE ↓ DOWN web_search No investment banks or underwriters have been named publicly for a WHOOP IPO as of April 2026. No S-1 has been filed with the SEC. No
14 MODERATE ↑ UP web_search WHOOP's $575M Series G round closed March 31, 2026 with high-profile institutional and sovereign wealth investors (QIA, Mubadala, Macquarie Capital), which could serve as preparatory signaling for an IPO but does not constitute formal IPO preparation. No
15 MODERATE ↑ UP web_search CEO Will Ahmed's public statements frame the Series G as 'the last private round,' a clear signal of IPO intent, but timeline remains vague ('next two years' from an unspecified date). No
16 MODERATE ↓ DOWN kalshi_data Kalshi prediction market prices WHOOP IPO before Jan 1, 2027 at 10%, down sharply 15 percentage points over both the past 7 and 30 days, suggesting the market recently received information pushing the probability down significantly. No
17 MODERATE ↓ DOWN kalshi_orderbook The Kalshi orderbook shows yes_bid=$0.01 and no_bid=$0.02 with high liquidity (depth=6000), suggesting the market is very confident in NO resolution — the spread and bids indicate near-consensus that WHOOP will not IPO before Jan 1, 2027. No
Information Gaps
  • No revenue, subscriber count, or profitability data for WHOOP has been publicly disclosed — making it impossible to assess IPO financial readiness objectively
  • No information on whether WHOOP has begun confidential S-1 (JOBS Act) filing processes, which would precede a public announcement
  • No data on whether WHOOP has hired investment banks or legal counsel for IPO preparation (not yet public even if underway)
  • The FDA warning letter outcome is unresolved — unclear if this regulatory dispute has been settled or is ongoing into 2026
  • No information on WHOOP's churn rate, customer acquisition costs, or LTV metrics that public market investors would scrutinize
  • Unclear what 'next two years' means in context — whether the CEO's November 2025 statement referred to 2026 or 2027 as the target
  • No data on lock-up obligations or investor pressure from earlier funding rounds (Series A-F) that might accelerate exit timeline
Key Uncertainties
  • Whether the Series G (March 2026) resets the clock on IPO timing — a fresh $575M round may reduce urgency to go public before Jan 2027
  • Resolution of the FDA blood pressure feature dispute — an ongoing regulatory battle could deter IPO bankers and investors
  • Whether 'announcing' an IPO (as required by the resolution criteria) means S-1 filing, public press release, or something else — timing of announcement vs. actual listing
  • Macro market conditions in H2 2026 — any significant market downturn could freeze the IPO window
  • Whether WHOOP pursues a confidential filing (which would not count as 'officially announcing') vs. a public S-1
  • The dramatic 15pp drop in Kalshi probability over 7 days suggests a specific catalyst (possibly the Series G announcement confirming no immediate IPO) — this information asymmetry is significant
Market Context
Price: 0.1 · 7d: -0.15 · 30d: -0.15
Volume: LOW-MODERATE — 118 avg daily contracts is thin for a definitive signal · Depth: HIGH — 6000 depth but extremely one-sided (yes_bid=$0.01 vs no_bid=$0.02)
Reliability: LOW-MEDIUM — the sharp 15pp decline over 7 days in a low-volume market suggests this may reflect a single catalyst (Series G announcement) but the orderbook strongly favors NO resolution; treat as directionally informative but not precise
4. Independent Forecaster Opus · No market price Did NOT see market price
Independent estimate: 15% (medium confidence)
sq1: Has WHOOP, Inc. already filed an S-1 or publicly announced IPO plans as of mid-2025?
5%
The evidence is clear: as of April 2026, WHOOP has NOT filed an S-1 or officially announced an IPO. The CEO has made statements about IPO intent ('next step,' 'last private round'), but these are aspirational statements, not official announcements. The Series G closed March 31, 2026, which strongly suggests no imminent IPO filing. This sub-question essentially asks about a past event that hasn't happened, so the probability is very low. The small residual probability accounts for the possibility of a confidential filing that we don't know about, or a very recent announcement not captured in the evidence.
sq2: Will WHOOP, Inc. achieve sufficient financial metrics to support an IPO by end of 2026?
55%
Base rate: Companies that raise at $10B+ valuations generally have strong enough metrics to eventually IPO, but the question is timing. The tripling of valuation from $3.6B to $10.1B suggests strong growth. Strategic investors (Abbott, Mayo Clinic) add credibility. However, the FDA warning letter is a significant risk factor — regulatory uncertainty can delay or derail IPOs. No revenue/profitability data is disclosed, which is unusual for a company truly IPO-ready. The subscription model is attractive but we can't verify scale. Net assessment: WHOOP likely has the financial trajectory but may not have IPO-grade financials polished and audited by end of 2026. The FDA issue pushes down ~10%. Strategic investors push up ~5%. Lack of disclosed metrics pushes down ~5%.
sq3: Will IPO market conditions be favorable enough for WHOOP to go public before Jan 1, 2027?
60%
Base rate: IPO windows tend to be open roughly 60-70% of the time in non-crisis periods. The evidence shows strong 2025 IPO recovery with successful high-profile listings (Circle, Klarna, Chime). S&P 500 at record highs in late 2025. However, we're forecasting through end of 2026 — 8-9 months of uncertainty remain. Any major macro shock (recession, geopolitical crisis, tariff escalation) could close the window. The evidence suggests conditions are currently favorable, pushing up from a ~50% base. But the 'return to normalcy' framing (not euphoria) and uncertainty about H2 2026 moderate the upside. Net: ~60%.
sq4: Has WHOOP hired underwriters/bankers signaling imminent IPO preparation?
25%
No investment banks or underwriters have been publicly named as of April 2026. No S-1 filed. The Series G just closed, which typically means the company is NOT about to IPO — you don't raise private capital at the same time you're preparing to go public. CEO's 'next two years' language from November 2025 suggests 2027-2028 as the likely target, not 2026. The base rate for a company that just raised a mega-round to immediately pivot to IPO within 9 months is low (~15-20%). The CEO's public statements about IPO intent push this up slightly, as do the strategic investors who might want liquidity. But the lack of any concrete IPO preparation signals keeps this low. ~25%.
Show full reasoning trace
base rate: Base rate for any specific private unicorn IPO-ing within an 18-month window is ~10-20%. However, the relevant window is now effectively ~9 months (April 2026 to Jan 2027). For a company that just raised $575M in March 2026, the base rate for announcing an IPO within 9 months of a mega-round is very low — perhaps 5-10%. Companies typically wait 18-36 months after their last private round before going public.
evidence updates: CEO's public IPO intent statements push UP by ~5% (from base). Series G framed as 'last private round' pushes UP by ~3%. Favorable IPO market conditions push UP by ~3%. But: Series G just closed March 2026 pushes DOWN by ~5% (reduces urgency). No S-1 filed or underwriters named pushes DOWN by ~3%. FDA warning letter pushes DOWN by ~2%. 'Next two years' vague timeline pushes DOWN by ~2%. Net from ~10% base: approximately 15%.
combination method: Weighted average of sub-questions, then adjusted downward because the sub-questions don't fully capture the strongest negative signal: the very recent mega-round that eliminates financial pressure to go public soon.
final: WHOOP has strong IPO intent signaled by CEO statements and the 'last private round' framing, but the March 2026 Series G at $10.1B significantly reduces the probability of an IPO announcement before Jan 1, 2027. The company now has $575M in fresh capital and no urgent need to access public markets. The FDA dispute adds further friction. Most likely timeline for an actual IPO announcement is 2027-2028. Probability of announcement before Jan 1, 2027: ~15%.
5. Devil's Advocate Sonnet Market price revealed
Asymmetric Evidence Math Error Over Anchored Generic Reasoning
Challenges
  1. The forecaster estimates 15% while the market says 10% — a 5% divergence that may seem small but is actually meaningful given the extremely one-sided orderbook (yes_bid=$0.01 vs no_bid=$0.02). The market is not just pricing 10%; it's signaling near-certainty of NO with the bid structure. The forecaster's reasoning doesn't provide a compelling independent justification for being 50% above the market price.
  2. The 'last private round' framing is being treated as a significant upward signal, but this is a common CEO talking point at late-stage fundraises that does NOT reliably predict a near-term IPO. Many companies have described rounds as 'the last before IPO' and then raised additional private capital 12-24 months later. This signal is weaker than the forecaster weights it.
  3. The sub-question structure has a mathematical inconsistency: sq1 is framed as a past event (has WHOOP already filed?) with p_yes=5%, but then the overall question is about 'when will WHOOP announce an IPO' — the combination logic between these sub-questions isn't explicitly stated. A 5% × 55% × 60% × 25% conditional chain would yield roughly 0.4%, far below 15%. The forecaster uses 'weighted average' instead, which inflates the result compared to a proper joint probability calculation.
  4. The evidence balance appears asymmetric in a misleading way: 10 UP vs 6 DOWN, but the forecaster's own reasoning identifies the Series G closing as the STRONGEST negative signal (it 'eliminates financial pressure'). Many of the 'UP' signals are redundant (multiple items about the strong IPO market, multiple items about investor quality) while each DOWN signal is structurally distinct. The directional count overstates the upward case.
  5. The forecaster's sq2 assigns 55% probability that WHOOP will achieve 'sufficient financial metrics to support an IPO by end of 2026' — but this is largely irrelevant given that the company JUST raised $575M in March 2026. Even if they have perfect metrics, there is almost zero institutional logic to announce an IPO within 9 months of a mega-round. This sub-question inflates the combined estimate without properly conditioning on the mega-round timing.
  6. The market's sharp 15pp decline over 7 days is treated as a single-catalyst artifact (Series G announcement), but this could also reflect sophisticated market participants pricing in information the forecaster doesn't have — e.g., direct knowledge that no IPO preparation is underway, or that the FDA dispute is unresolved. The forecaster dismisses this signal too quickly given the 'LOW-MEDIUM reliability' label.
  7. The forecaster's base rate analysis is inconsistent: they cite '10-20% for any unicorn in 18-month window' but then correctly adjust to 5-10% for 9 months post-mega-round — yet the final estimate of 15% is ABOVE even the more generous 18-month base rate, which requires strong positive evidence that isn't clearly present beyond aspirational CEO statements.
Suggested adjustment: -4pp
Decrease by 4 percentage points toward the market's 10-11% range. The orderbook structure (yes_bid=$0.01) suggests informed participants see this as near-impossible in the timeframe. The joint probability of all necessary conditions (financial readiness, market conditions, no FDA obstruction, willingness to IPO 9 months post-mega-round) is likely below 10% when properly multiplied rather than averaged. The 'last private round' signal is weak historically. The forecaster's 15% estimate implicitly relies on the weighted average method that inflates versus a conditional chain approach, and the strongest DOWN signal (just-closed mega-round) is underweighted relative to its structural significance.
Market comparison: Forecaster: 15%, Market: 10%. The 5% divergence is not large in absolute terms but is significant given market direction (down 15pp in 7 days) and the orderbook structure showing near-zero yes-side interest. The forecaster's independent reasoning doesn't provide sufficiently strong specific evidence to justify being 50% above market price. The 'last private round' and CEO statement signals are generic and historically unreliable as near-term IPO predictors. The market price is directionally more consistent with the structural reality of a company 9 months post-$575M fundraise.
6. Final Forecast Opus
10% (medium confidence)
I ACCEPT most of the Devil's Advocate critiques. Challenge 3 (math inconsistency) is valid — a proper conditional chain of the sub-questions yields a much lower probability than my weighted average approach. Challenge 5 is correct that the March 2026 $575M Series G is the dominant signal: there is virtually no institutional logic for a company to announce an IPO within 9 months of closing a mega-round at $10.1B valuation. Challenge 2 rightly notes that 'last private round' is a common CEO talking point that doesn't reliably predict near-term IPOs. Challenge 7 correctly identifies that my 15% estimate exceeded even my own 18-month base rate despite the compressed 9-month window. The market at 10% with a strongly one-sided orderbook is consistent with the structural reality, and I lack specific evidence (such as named underwriters, S-1 filing, or concrete timeline commitments) to justify deviating upward from it. The residual 10% probability reflects the non-zero chance that WHOOP's strategic investors (Abbott, Mayo Clinic) push for a rapid public listing or that market conditions create an irresistible IPO window.
Pipeline Timing
StepTime
Planning 16.01s
Research 42.8s
Synthesis 47.08s
Forecaster 32.63s
Critic 26.98s
Final 10.07s